WO2019107671A1 - 항-ros1 항체 및 그의 용도 - Google Patents
항-ros1 항체 및 그의 용도 Download PDFInfo
- Publication number
- WO2019107671A1 WO2019107671A1 PCT/KR2018/002655 KR2018002655W WO2019107671A1 WO 2019107671 A1 WO2019107671 A1 WO 2019107671A1 KR 2018002655 W KR2018002655 W KR 2018002655W WO 2019107671 A1 WO2019107671 A1 WO 2019107671A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- antibody
- antigen
- amino acid
- acid sequence
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/10—Protein-tyrosine kinases (2.7.10)
- C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
Definitions
- hybrids monoclonal antibodies are made using hybridoma technology, and these monoclonal antibodies are specified by hybridoma cell lines deposited in an approved cell line depository.
- R0S1 protein is cleaved and the 30 regions of R0S1 are divided into v-ros, FIG, SLC34A2, CD74, EZR, LRIG3, and TPM3.
- R0S1 is known to activate cell signaling associated with proliferation, metastasis, and anti-apoptotic function, but its biological function has not been elucidated.
- the specificity may be one having more enhanced characteristics.
- One example provides an anti-R0S1 antibody or an antigen-binding fragment thereof that specifically recognizes the N-terminal region of the ROS1 protein.
- the R0S1 protein may be a human ROS1 (e.g., NP_002935.2 (SEQ ID NO: 9), etc.).
- the N-terminal region of the R0S1 protein may be the 37th to 290th region or a portion thereof in the amino acid sequence of the R0S1 protein (SEQ ID NO: 9), and the portion may be, for example, 56, or a part thereof (e.g., D46-L47-G48-T49
- the anti-R0S1 antibody or antigen-binding fragment thereof comprises an amino acid 39-56 of R0S1 (NP_002935.2; SEQ ID NO: 9) or a portion thereof (eg, D46-L47-G48-T49 of R0S1 ) Or the amino acid of L45-D46-L47-G48-T49 (SEQ ID NO: 11).
- the anti-R0S1 antibody or antibody-derived antigen binding fragment comprises or consists of D46-L47-G48-T49 (SEQ ID NO: 10) or L45-D46-L47-G48-T49 (SEQ ID NO: It is possible to specifically recognize (and / or bind) an epitope that has been made essentially.
- the anti-R0S1 antibody or antigen-binding fragment thereof provided herein may not bind to a peptide consisting of IDLGT (SEQ ID NO: 12).
- the peptide consisting of IDLGT may be present in HSP family proteins such as Heat shock protein 70 (HSP70), HSP71, GRP75 and GRP78.
- HSP70 Heat shock protein 70
- HSP71 HSP71, GRP75 and GRP78.
- the anti-R0S1 antibody or antigen-binding fragment thereof provided herein may not bind to HSP family proteins such as HSP70, HSP71, GRP75 and GRP78.
- the anti-R0S1 antibody or antigen-binding fragment thereof may comprise the following complementarity determining region (3 R): 2019/107671 1 »(: 1 ⁇ ⁇ 2018/002655
- SEQ ID NO: 60 or SEQ ID NO: 13 (( ⁇ ), particularly SEQ ID NO: 60).
- Another example provides use for use in the diagnosis of cancer of the anti-salvage antibody or antibody-derived antigen binding fragment, or for use in the preparation of an anti-cancer agent or cancer diagnostic agent.
- Another example is the ability of the anti-R0S1 antibody to increase the specificity for ROS1
- the epitope may be located at the N-terminal site of the ROSl protein (e. (For example, the region from 37 th to 290 th in the amino acid sequence of NP_002935.2 (SEQ ID NO: 9)) or a part thereof (for example, four or more consecutive or five or more consecutive , 6, 7, 8, 9, or 1 ⁇ amino acid), or a portion thereof.
- the ROSl protein e. (For example, the region from 37 th to 290 th in the amino acid sequence of NP_002935.2 (SEQ ID NO: 9)
- a part thereof for example, four or more consecutive or five or more consecutive , 6, 7, 8, 9, or 1 ⁇ amino acid
- the epitope of ROS1 comprises a region from position 39 to 56 of the ROS1 protein (SEQ ID NO: 9), or a portion thereof (e.g., D46-L47-G48-T49 -G48-T49 (SEQ ID NO: 11)).
- Another example is
- One example provides a method for enhancing the specificity of an anti-R0S1 antibody, including introducing a point mutation into the heavy chain complementarity determining region 3 (HCDR3).
- a method of enhancing the specificity of an anti-R0S1 antibody comprises the step of replacing glycine (G), the first amino acid of H3 R3 of an antibody or antigen-binding fragment thereof comprising the following CDRs with raisin can do:
- LCDR1 SGGSYGYG (SEQ ID NO: 1)
- LCDR2 DNTNRPS (SEQ ID NO: 2)
- LCDR3 GSADSSSIAT (SEQ ID NO: 3)
- HCDR1 GFSFSDRGMH (SEQ ID NO: 4),
- HCDR2 ISGDGYITHYGAAVKG (SEQ ID NO: 5), and
- HCDR3 GGGGNIDA (SEQ ID NO: 13).
- SEQ ID NO: 2 IXDR3 (SEQ ID NO: 3), H (SEQ ID NO: 4), H (SEQ ID NO: ), A heavy chain variable region (SEQ ID NO: 8 or SEQ ID NO: 13), and a scFv (SEQ ID NO: 24 or SEQ ID NO: 26).
- the recombination vector may comprise or comprise the light chain variable region (SEQ ID NO: 7) and the heavy chain variable region (SEQ ID NO: 8 or SEQ ID NO: 14, respectively).
- the recombinant vector may comprise the anti-R0S1 scFv (SEQ ID NO: 24 or SEQ ID NO: 26).
- Another example provides a recombinant cell comprising said recombinant vector.
- Another example provides a method for producing an anti-R0S1 antibody or antigen-binding fragment thereof, comprising the step of expressing the recombinant cell.
- the R0S1 protein is a proto-oncogene tyrosine kinase encoded by the ROS1 gene and plays an important role in carcogenesis through the rearrangement of genes and the formation of fusion proteins with other genes involved in the C-terminal intracellular region of R0S1 .
- the possibility of overexpression of wild-type ROS1 through epigenet ic regulat ion has been proposed.
- an anti-ROS1 antibody (3B20) is provided that binds to the N-terminus of ROSl, which can be used to detect wild-type ROS1 in cancer tissues (e.g., cancerous tissues).
- cancer tissues e.g., cancerous tissues.
- the ability of 3B20 to react with heat shock proteins e.
- Hsp70s has been identified through conventional analytical techniques such as immunoblotting and immunoprecipitation.
- the amino acid sequence of ROS1 and the amino acid sequence of Hsp70s were analyzed to confirm that these sequences shared the amino acid sequence. Through an alanine substitution mutation test of R0S1, it was confirmed that the epitope of ROS1 contained the above sequence.
- Anti-R0S 1 antibody (3B20) H 3 Randomly replacing each amino acid constituting R 3 with an amino acid different from the original amino acid.
- the mutant clone 3B20-G1K which has cross reactivity to react with other proteins (such as Hsp70s) while retaining its reactivity (binding force) with ROS1 through mutation, was prepared.
- R0S1 is not observed in normal tissue (e.g., normal lung tissue) using 3B20-G1K, whereas R0S1 is overexpressed in lung cancer tissue (e.g., lung tissue with lung adenocarcinoma) Respectively.
- normal tissue e.g., normal lung tissue
- lung cancer tissue e.g., lung tissue with lung adenocarcinoma
- the present specification provides an epitope of ROS1, an anti-ROS1 antibody or antigen-binding fragment thereof specifically recognizing the epitope, and the use of the antibody, which can enhance the specificity for ROS1.
- the anti-R0S1 antibody or antigen-binding fragment thereof may be characterized in that the specificity for ROS1 is further enhanced by recognizing a specific region of ROS1.
- One example provides an anti-R0S1 antibody or an antigen-binding fragment thereof that specifically recognizes the N-terminal region of the ROS1 protein.
- the R0S1 protein may be a human ROS1 (e.g., NP_002935.2 (SEQ ID NO: 9), etc.).
- the N-terminal region of the R0S1 protein may be the 37th to 290th region or a portion thereof in the amino acid sequence of the R0S1 protein (SEQ ID NO: 9), and the portion may be, for example, (For example, amino acids of D46-L47-G48-T49 (SEQ ID NO: 10) or L45-D46-L47-G48-T49 (SEQ ID NO: 11)).
- the anti-R0S1 antibody or antigen-binding fragment thereof comprises amino acids 39-56 of R0S1 (NP_002935.2; SEQ ID NO: 9) or a portion thereof (e.g., D46-L47-G48-T49 of SEQ ID NO: Or amino acid of L45-D46-L47-G48-T49 (SEQ ID NO: 11)).
- An epitope comprising or consisting essentially of D46-L47-G48-T49 (SEQ ID NO: 10) or L45-D46-L47-G48-T49 (SEQ ID NO: 11) can be specifically recognized.
- the anti-R0S1 antibody or antigen-binding fragment thereof may not bind (and / or recognize) a peptide composed of IDLGT (SEQ ID NO: 12).
- the peptide consisting of IDLGT may be present in HSP family proteins such as Heat shock protein 70 (HSP70), HSP71, GRP75 and GRP78.
- HSP70 Heat shock protein 70
- HSP71 HSP71
- GRP75 GRP78
- this protein does not bind to this protein, such as 70, 70, 075, and 78.
- the anti-human antibody or antigen-binding fragment thereof binds (and / or recognizes) a peptide consisting of 145-046-147-048-149 (SEQ ID NO: 11) and 1 (SEQ ID NO: 12) It may be possible.
- the anti-urine and the antibody or antigen-binding fragment thereof may be at least one kind selected from the group consisting of sputum proteins 70, 71, 0175 and 78, (And / or recognizable) to more than one species, to more than four species, or to all five species.
- the anti-salvage antibody or antigen-binding fragment thereof may comprise the following complementarity determining regions (3):
- the anti-CD4 antibody or antigen-binding fragment thereof may comprise the following variable regions:
- the anti-R0S1 antibody or antigen-binding fragment thereof may be an anti-R0S1 antibody or antigen-binding fragment thereof, defined as:
- an anti-R0S1 antibody or an antigen-binding fragment thereof comprising: (a) a complementary determining region (CDRs)
- LCDR1 comprising the amino acid sequence of SEQ ID NO: 1 (SGGSYGYG), LCDR2 comprising the amino acid sequence of SEQ ID NO: 2 (DNTNRPS)
- An LCDR3 comprising the amino acid sequence of SEQ ID NO: 3 (GSADSSSIAT).
- HCDR1 comprising the amino acid sequence of SEQ ID NO: 4 (GFSFSDRGMH), HCDR2 comprising the amino acid sequence of SEQ ID NO: 5 (ISGDGYITHYGMVKG), and
- HCDR3 comprising the amino acid sequence of SEQ ID NO: 6 (KGGGNIDA); or
- an anti-R0S1 antibody or antigen-binding fragment thereof comprising the following variable regions:
- a light chain variable region comprising the amino acid sequence of SEQ ID NO: 7, and
- a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 8,
- the anti-R0S1 antibody or antigen-binding fragment thereof may bind to SEQ ID NO: 11 (LDLGT) and not to SEQ ID NO: 12 (IDLGT) .
- the anti-R0S1 antibody or antigen-binding fragment thereof may be an anti-R0S1 antibody or antigen-binding fragment thereof, defined as follows:
- an anti-R0S1 antibody or antigen-binding fragment thereof comprising the following complement determining region (CDRs):
- LCDR1 comprising the amino acid sequence of SEQ ID NO: 1 (SGGSYGYG)
- An LCDR2 comprising the amino acid sequence of SEQ ID NO: 2 (DNTNRPS)
- An LCDR3 comprising the amino acid sequence of SEQ ID NO: 3 (GSADSSSIAT).
- HCDR1 comprising the amino acid sequence of SEQ ID NO: 4 (GFSFSDRGMH), HCDR2 comprising the amino acid sequence of SEQ ID NO: 5 (ISGDGYITHYGMVKG), and
- HCDR3 comprising the amino acid sequence of SEQ ID NO: 13 (GGGGNIDA); or
- a light chain variable region comprising the amino acid sequence of SEQ ID NO: 23 and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 14, wherein the anti-1/3 antibody or antigen binding fragment thereof comprises SEQ ID NO: ), And SEQ ID NO: 12 ( ⁇ liver). Due to this feature, one or more selected from the group consisting of 0, 3 ⁇ 4 70 , 3 ⁇ 4 71 , 0 75 and 0 78 Or more, 3 kinds or more, 4 kinds or more, or 5 kinds.
- the antigen-binding fragment of the anti-1/4 antibody comprises 10 of the above-mentioned anti-Yo and 6 of the antibody Any polypeptide comprising, e. (Kappa constant region), 1 - (: 1 (lambda constant region),
- the antigen-binding fragment comprises 1% or Immunoglobulins (e. G., Fusion sites and fused
- a pharmaceutical composition comprising the anti-13 ⁇ 4) and the antibody or antibody-derived antigen-binding fragment.
- the pharmaceutical composition 25 may be a composition for diagnosing cancer.
- Another example provides the use for use in the diagnosis of cancer of the anti-human and antibody or antibody-derived antigen-binding fragment, or for use in the manufacture of an anti-cancer agent or cancer diagnostic agent.
- a method for diagnosing cancer or a method for providing information to diagnosis of cancer can be carried out by confirming whether the antigen-antibody complex is formed (detecting the complex) by a conventional method.
- the biological sample may be selected from the group consisting of (isolated) cells, tissues, body fluids and cultures thereof obtained from an object (for example, a mammal such as a human).
- the method for providing information on the diagnosis method of cancer or the diagnosis of cancer is characterized in that after the step (2)
- step (3) If the antigen-antibody reaction in the reactant of step (1) is confirmed (e.g., formation of an antigen-antibody complex is confirmed (complex detected), the subject is at risk of developing cancer or cancer Determination (or confirmation) of the information.
- the epitope may be located at the terminal end of a protein (e. / ⁇ ( 6331011 ). Or a part thereof (for example, in the region from the 37th to the 290th in the amino acid sequence of SEQ ID NO: 9) or a part thereof (for example, 4 or more consecutive or 5 consecutive Or more of the above amino acids).
- the epitope with the tide is the region 39 to 56 of SEQ ID NO: 9 (SEQ ID NO: 15), or a portion thereof (e.g.,
- SEQ ID NO: 10 or one amino acid of 5-046 DOO 47 48 49 (SEQ ID NO: 11) or SEQ ID NO: 10 or SEQ ID NO: 11 in SEQ ID NO: Or a site comprising or consisting of 5 or more amino acids).
- Another example is
- the antibody or antigen-binding fragment specifically binds to a gonad comprising the antibody or antigen-binding fragment thereof.
- the selected antibody or antigen-binding fragment is one that is capable of binding to SEQ ID NO: 11 (1) and SEQ ID NO: 12 (1) And 1 3 ⁇ 4 light 1, 2019/107671 1 »(: 1 ⁇ ⁇ 2018/002655
- the selected antibody or antigen binding fragment binds to SEQ ID NO: 11 (1 ⁇ Jiang, SEQ ID NO: 12
- SEQ ID NO: 11 1011 Jiang
- the selected antibody or antigen binding fragment binds to SEQ ID NO: 11 (1 ⁇ Jiang, SEQ ID NO: 12
- the recombinant vector may comprise or comprise the light chain variable region (SEQ ID NO: 7) and the heavy chain variable region (SEQ ID NO: 8 or SEQ ID NO: 14, respectively).
- the recombinant vector may comprise the anti-CDNA ⁇ SEQ ID NO: 24 or SEQ ID NO: 26).
- Another example provides a recombinant cell comprising said recombinant vector.
- Another example provides a method of producing an anti-antibody or antigen-binding fragment thereof, comprising the step of expressing the recombinant cell.
- the urine that acts as an antigen of the antibody or antigen-binding fragment provided herein may be of mammalian origin, for example, (E.g., GenBank accession numbers NP_002935.2, etc.).
- the anti-R0S1 antibody provided herein recognizes and / or binds to the N-terminal portion of R0S1 (i.e., the epitope region described above).
- the term " antibody " refers collectively to a protein specifically binding to a specific antigen, and may be a protein produced by stimulation of an antigen in the immune system or a protein prepared chemically or recombinantly , The kind thereof is not particularly limited.
- the antibody may be an unnatural one, for example, recombinantly or synthetically produced.
- the antibody may be an animal antibody (e.g., mouse antibody, etc.), a chimeric antibody, a humanized antibody or a human antibody.
- the antibody may be a monoclonal antibody or a polyclonal antibody.
- a complete antibody is a structure with two full length light chains and two full length heavy chains, each light chain linked by a heavy chain and a disulfide bond.
- the constant region of the antibody is divided into a heavy chain constant region and a light chain constant region and the heavy chain constant region has gamma U), mu (U), alpha U), delta (5) gamma 2 (Y 2), gamma 3 (Y 3), gamma 4 (Y 4), alpha 1 (a 1) and alpha 2 (a 2).
- the constant region of the light chain has the kappa (K) and lambda (X) types.
- variable chain refers to a variable region domain V H comprising an amino acid sequence having a sufficient variable region sequence sufficient to impart specificity to an antigen and three constant region domains C HI, C H2 and C H3 , quot; includes both a full-length heavy chain including a hinge and fragments thereof.
- light chain also encompasses both the full-length light chain comprising the variable region domain V L and the constant region domain C L comprising the amino acid sequence having a sufficient variable region sequence to confer specificity to the antigen and fragments thereof Is interpreted to mean inclusive.
- CDR complementarity determining region
- an antibody can be understood to include an antigen-binding fragment of an antibody that retains antigen-binding ability, unless otherwise specified.
- antigen-binding fragment refers to any form of polypeptide comprising a moiety capable of binding an antigen (eg, 6 (3) R as defined herein).
- an antigen eg, 6 (3) R as defined herein.
- the antigen-binding fragment may be a scFv, or a scFv that is fused with an Fc region of an immunoglobulin (e.g. IgGl, IgG2, IgG3, IgG4, etc.) or a constant region of a light chain (e.g. kappa or lambda) Lt; / RTI > polypeptide.
- Fab among the antigen-binding fragments has one variable region of light and heavy chains, a constant region of light chain and a first constant region (C H1) of heavy chain, and has one antigen-binding site.
- the F (ab ') 2 antibody is produced when the cysteine residue of the hinge region of the Fab forms a disulfide bond.
- Recombinant techniques for generating Fv fragments with minimal antibody fragments having only a heavy chain variable region and a light chain variable region are well known in the art.
- Double chain Fv (two-chain Fv) is the heavy chain variable region and light chain variable region linked to a non-covalent bond
- single chain Fv (s ingl e ⁇ chain Fv ) is generally the variable region of the heavy chain through a peptide linker, a variable region and a short chain Is connected to the covalent bond or is directly connected to the C-terminal, so that a dimer-like structure can be obtained like the double-chain Fv .
- the antigen-binding fragment can be obtained using a protein hydrolyzing enzyme (for example, when the whole antibody is restricted to papain, a Fab can be obtained and when cut with pepsin, an F (ab ') 2 fragment can be obtained) It can be produced through recombinant DNA technology.
- a protein hydrolyzing enzyme for example, when the whole antibody is restricted to papain, a Fab can be obtained and when cut with pepsin, an F (ab ') 2 fragment can be obtained
- It can be produced through recombinant DNA technology.
- the term "hinge region” is a region contained in the heavy chain of the antibody, which exists between the CH1 and CH2 regions and which functions to provide the flexibility (antigenicity) of the antigen binding site in the antibody The area is known.
- the anti-R0S1 antibody may be a monoclonal antibody.
- Monoclonal antibodies can be prepared by methods well known in the art. For example, it can be prepared using the phage di sp l ay technique. Alternatively, the anti-R0S1 antibody can be prepared and used as a monoclonal antibody derived from a mouse by a conventional method.
- individual monoclonal antibodies can be screened based on their ability to bind to R0S1 using a typical ELISA (Enzyme-Linked ImmunoSorbent Assay) format. Can be assayed for inhibitory activity through functional assays such as competitively EL ISA (Competitve ive ELISA) or CE-based assays for assaying molecular interactions for the conjugates have. Each affinity for R0S1 (Kd va lues) can then be assayed for selected monoclonal antibody members based on strong inhibitory activity. The finally selected antibodies can be used as humanized antibodies as well as human immunoglobulin antibodies except for the antigen binding portion. Methods for making humanized antibodies are well known in the art.
- the patient to which the present invention is applied may be a mammal including a primate including a human, a monkey, etc., a rodent including a mouse, a rat, and the like.
- the cancer is a solid tumor or blood may amil, but are not limited to, lung cancer (e.g. small cell lung cancer, non-small cell lung cancer, lung cancer, lung squamous cell carcinoma, etc.), peritoneal cancer, skin cancer, cutaneous or intraocular melanoma, colon cancer, around the anus (Eg chronic or acute leukemia), lymphoma, hepatocellular carcinoma, gastrointestinal cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, endometrioid carcinoma, A cancer selected from the group consisting of liver cancer, bladder cancer, liver cancer, breast cancer, colon cancer, colon cancer, endometrial or uterine cancer, salivary cancer, kidney cancer, liver cancer, prostate cancer, mucin cancer, thyroid cancer, liver cancer, head and neck cancer, It can be more than a species.
- the cancer may be a primary cancer or a metastatic cancer.
- the anti-R0S1 antibody or antigen-binding fragment thereof specifically binds to the N-terminal region of ROS1, particularly ROS1 (for example, the epitope region described above), so that ROS1 can be detected or confirmed.
- another embodiment of the present invention provides a composition for detecting ROS, comprising the anti-ROS1 antibody or antigen-binding fragment thereof.
- Another example includes treating the biological sample with the anti-R0S1 antibody or antigen-binding fragment thereof; And a step of confirming whether or not the antigen-antibody reaction is confirmed. In this detection method, when the antigen-antibody reaction is confirmed (antigen-antibody Complex is detected), it can be determined that ROS1 is present in the biological sample.
- the detection method may further comprise, after the identifying step, determining that ROSl is present in the biological sample if an antigen-antibody reaction is detected.
- the biological sample may be selected from the group consisting of (isolated) cells, tissues, body fluids, cultures thereof, etc. obtained from a mammal such as a human (for example, a cancer patient).
- the step of confirming whether an antigen-antibody reaction is confirmed can be performed through various methods known in the art. For example, it can be measured by a conventional enzyme reaction, fluorescence, luminescence and / or radiation detection, and specifically, immunochromatography,
- Immunohistochemical staining (Clmmunohy stoichiometry), enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), enzyme immunoassay (EIA), fluorescence immunoassay but are not limited to, immunoassay (FIA), luminescence immunoassay (LIA), Western blotting, microarray, and the like.
- the heavy chain complementarity determining region, the light chain complementarity determining region, or a combination thereof of the anti-R0S1 antibody described above Or a polypeptide chain comprising a heavy chain variable region, a light chain variable region , or a combination thereof .
- the polypeptide molecule can be used as a precursor of an antibody as well as a component of a protein scaffold (e.g., a peptibody), a bispecific antibody, a multispecific antibody, have.
- Another example provides nucleic acid molecules encoding heavy chain complementarity determining regions, heavy chain variable regions or heavy chains of anti-R0S1 antibodies.
- Another example provides nucleic acid molecules encoding light chain complementarity determining regions, light chain variable regions or light chains of anti-R0S1 antibodies.
- heavy chain complementarity determining region of the anti-R0S1 antibody examples include the heavy chain complementarity determining region of the anti-R0S1 antibody, the nucleic acid molecule encoding the heavy chain variable region or heavy chain, and the light chain
- a recombinant vector containing a nucleic acid molecule encoding a complementarity determining region, a light chain variable region or a light chain is contained in one vector or each vector in a separate vector.
- vector means means for expressing a gene of interest in a host cell.
- viral vectors such as plasmid vectors, cosmid vectors and bacteriophage vectors, lentivirus vectors, adenovirus vectors, retroviral vectors, and adeno-associated viral vectors.
- Vectors that can be used with the recombinant vector include, for plasmid (for example, often used in the art, pSClOl, pGV1106, pACYC177, ColEl , P KT230, pME290, pBR322, pUC8 / 9, pUC6, pBD9, pHC79, pIJ61, pLAFRl, (e.g., pHV14, pGEX series, pET series, pUC19, etc.), phage (e.g., A gt4XB, X-Charon, Aza1 and M13) or viruses (e.g., SV40, etc.) .
- plasmid for example, often used in the art, pSClOl, pGV1106, pACYC177, ColEl , P KT230, pME290, pBR322, pUC8 / 9, pUC6, pBD9, pHC79, pIJ
- the nucleic acid molecule in the recombinant vector may be operatively linked to a promoter.
- the term " operatably linked" refers to a functional linkage between a nucleotide expression control sequence (e.g., a promoter sequence) and another nucleotide sequence.
- the regulatory sequence may be operatively linked to regulate transcription and / or translation of other nucleotide sequences.
- the recombinant vector can typically be constructed as a vector for cloning or as a vector for expression.
- the expression vector may be any conventional vector used in the art to express an exogenous protein in plants, animals or microorganisms.
- the recombinant vector can be constructed through a variety of methods known in the art.
- the recombinant vector may be constructed with prokaryotic or eukaryotic cells as hosts.
- a strong promoter capable of promoting transcription for example, a pL A promoter, a CMV promoter, a trp promoter, a lac promoter, a tac promoter, T7 promoter, etc.
- a ribosome binding site for initiation of translation and a transcription / translation termination sequence for example, a pL A promoter, a CMV promoter, a trp promoter, a lac promoter, a tac promoter, T7 promoter, etc.
- the origin of replication that functions in the eukaryotic cells contained in the vector is the origin of cl replication, the origin of SV40 replication, the origin of replication of pMBl, the origin of adenope replication, the origin of AAV replication, but are not limited thereto.
- promoters derived from the genome of mammalian cells e.g., metallothionein promoter
- mammalian viruses e.g., adenovirus late promoter, vaccinia virus 7.5K promoter, SV40 promoter, Cytomegalovirus promoter and promoter of HSV
- adenovirus late promoter vaccinia virus 7.5K promoter
- SV40 promoter vaccinia virus 7.5K promoter
- the recombinant cell may be obtained by introducing the recombinant vector into an appropriate host cell.
- the host cell may be any host cell known in the art as a cell capable of successively cloning or expressing the recombinant vector stably.
- Examples of the prokaryotic cell include E. coli JM109, E. coli Bacillus subtilis, Bacillus subtilis, and Bacillus strains such as E. coli RR1, E. coli LE392, E. coli B, E. coli X1776, E.
- coli W3110 Bacillus subtilis, and Salmonella typhimurium, Yeast, Saccharomyces cerevisiae), gut cells, plant cells, and animal cells, such as, for example, E. coli, S. cerevisiae, HEK293T, Sp2 / 0, CHOCChinese hamster ovary) K1, CHO DG44, PER.C6, W138, BHK, COS-7, 293, HepG2, Huh7, 3T3, RIN, MDCK cell lines, no.
- the transfer (introduction) of the nucleic acid molecule or the recombinant vector containing the nucleic acid molecule into a host cell can be carried out by a method well known in the art.
- the host cell is a prokaryotic cell
- the CaCl 2 method or the electroporation method can be used.
- the host cell is a eukaryotic cell
- the microinjection method, the calcium phosphate precipitation method, the electroporation method, Liposome-mediated transfection methods, and gene bombardment but the present invention is not limited thereto.
- the method of screening the transformed host cells can be easily carried out according to methods well known in the art, using phenotypes expressed by selection markers.
- the selection mark is a specific antibiotic resistance gene
- the transformant can be easily selected by culturing the transformant in a medium containing the antibiotic.
- the method of manufacture may include culturing the recombinant cells comprising the recombinant vector, and optionally isolating and / or purifying the antibody from the culture medium.
- an anti-rROS1 antibody or antigen-binding fragment thereof that reacts with the N-terminal region of ROSl wherein the epitope is ROS1 (NPJ302935.2; L47-G48-T49 of SEQ ID NO: 9).
- the antibody binding to D46-L47-G48-T49 of R0S1 could cross-react with Hsp70s having the same DLGT sequence, and mutation (for example, amino acid substitution ) was introduced to further increase the specificity of the antibody. From the IDLGT sequence of Hsp70, an antibody that accurately discriminates the LDLGT sequence of ROS1 is provided.
- the present specification provides an anti-R0S1 antibody that specifically binds to the R0S1 N-terminal region, thereby enabling more accurate and efficient detection of R0S1 (N-terminal or full-length), a study of the biological function of R0S1, And can be usefully used for diagnosis of related diseases.
- Figure la is a graph showing the amount of 3B20 scFv-rFc fusion protein bound to ROS1.
- Figure lb shows the result of immune precipitation of HEK293T cells transfected with a lentiviral vector encoding human ROS1 (full-l eng) and lysates by immunoprecipitation with 3B20 scFv-rFc fusion protein and confirmed by immunoblotting.
- Figure lc shows the GFP (control; 3B20 antibody treated with a lentiviral vector of HEK293T cells transformed with a lentiviral vector encoding ROS (C) or ROS1 (R), followed by MS analysis of immunoprecipitated and isolated protein fractions.
- FIGS. 2A to 2C show the results of identification of the 3B20 epitope by alanine substitution mutagenesis at the Gly42 to Ser54 regions of the human ROS1 protein, wherein 2a is a 3B20 scFv-CK fusion protein, 2b is BSA, 2c is an i rrel evant scFv - K K fusion proteins to alanine substituted mutants, respectively.
- Figures 3a and 3b show the results of ELISA for the reaction specificity of 3B20 and 3B20-G1K on the recombinant ROS1 (amino acid 37-290) -CK fusion protein, 3a 3B20, and 3b is the result of 3B20-G1K.
- Figure 3c shows a 3B20, 3B20-G1K, or R0S1 antibody (Abeam product number ab5512) was added to a lysate of HEK293T cells transformed with the R0S1 coding lentiviral vector (lane R) or the control vector (lane C; GFP) Immunoblotting results obtained by treatment are shown.
- FIG. 3D shows the result of immunoprecipitation of 3B20 or 3B20-G1K with a lysate of HEK293T cells transformed with the R0S1 coding lentiviral vector (lane R) or the control vector (lane C; GFP).
- FIG. 4 shows immunohistochemical staining (IHC) results using 3B20-G1K.
- the synthetic peptide (TNLGQQLDLGTPHNLGPGGC (SEQ ID NO: 16); R0S1 (GenBank Accession No. NPJ302935.2) conjugated to keyhole limpet hemocyanin (Peptron; Daejun, S. Korea)
- scFv Chicken single-chain variable fragment
- BSA Bovine serum albumin
- OVA ovalbumin
- ELISA enzyme-1 inked immunosorbent assay
- the gene encoding the selected scFv (3B20) was subcloned into modified pCEP4 mammalian expression vectors (V04450; Thermo Fisher Scientific, Rockford, Ill., USA) Fusion protein (scFv (3B20) -rFc fusion protein) fused with Fc (rFc) [H. Kim, S. Park, HK Lee, J. Chung, Application of bispecific antibodies against antigen and hapten for immunodetection and immunopurification, Exp. Mol. Med. 45 (2013) e43. Or a fusion protein (scFv-CK fusion protein) in which the ScFv is fused with a human kappa light chain constant region (CK) [Y. Lee, H.
- CK fusion protein, irrelevant protein (prostate cancer specific antigen (NP_001025218.1)), a recombinant ROS1 (37-290 amino acid) -cK fusion protein (Costar, Cambridge, Mass., USA) was coated with a coating solution in which a synthetic peptide (TNLGQQLDLGTPHNL condition PGGG-BSA conjugate or GRP75 (Enzo Life Sciences, Farmingdale, NY, USA) was dissolved in 0.1 M sodium bicarbonate, pH 8.6. After blocking, 3B20 -rFc or 3B20-G1K (the first amino acid G of HCDR3 of 3B20 was replaced with K) -rFc fusion protein was added.
- a synthetic peptide TNLGQQLDLGTPHNL condition PGGG-BSA conjugate or GRP75 (Enzo Life Sciences, Farmingdale, NY, USA
- the amount of antibody bound was determined using horseradish peroxidase (HRP) -conjugated goat anti- rabbit IgG antibody (Abeam, (Amersco LLC, Solon, OH, USA) was used as a substrate solution in the presence of 2, 20-azinobis [3-ethylbenzothiazol ine-6-sul fonic acid] The amount of antibody bound to each sample was measured. It was performed.
- HRP horseradish peroxidase
- Abeam (Amersco LLC, Solon, OH, USA) was used as a substrate solution in the presence of 2, 20-azinobis [3-ethylbenzothiazol ine-6-sul fonic acid]
- microtiter plates (Corning Costar) were incubated with 3B20 scFv-CK fusion protein 100 ng of bovine serum albumin, or 100 ng of irrelevant SCFV-CK overnight at 4 ° C.
- the plate was incubated with an alanine-substituted ROS1-human antibody Fc (hFc) fusion protein (the 42nd amino acid residue of ROS1 (from the 54th amino acid residue (Ser) replaced by each alanine) or wild type ROS1- hFc fusion protein
- hFc alanine-substituted ROS1-human antibody Fc
- the amount of fusion protein bound to the plate was measured using HRP-conjugated rabbit anti-human IgG Fc antibody (Thermo Fisher
- Human ROS1 Open Biosystems, Huntsville, AL
- Gateway recombinant coolding technology and Gateway LR Clonase TM (Thermo Fisher Scientific) to construct pLent i 6-human ROS- , USA) with pLent i6 / V5-DEST (Thermo Fisher Scientific,
- GFP green fluorescent protein
- Lentiviruses were then produced with reference to the following references: [J. Yin, G. Park, T.H. Kim, J.H. Hong, Y.J. Kim, X. J, S. Kang, J.E. Jung,
- PEDF Pigment epithelium-derived factor
- the cells were cultured in HEK293T cells (American Type Culture Collection, Manassas, VA USA) in the presence of 6 g / mL polybrene using the prepared pLent i 6-human
- R0S1-DEST or GFP lentivirus as described [J. HES1 and SIRT1 expression, Oncotarget, Gene Park, JE Lee, JY Park, TH Kim, YJ Kim, SH Lee, H. Yoo, JH Kim, JB Park, CPEB1 modulates differentiation of glioma stem cells 5 (2014) 6756 [6769].
- GIBC0 Grand Island, NY, USA
- the resulting cell lysate was incubated with 3B20 scFv or 3B20 scFv-GIK fused with rFc fusion protein 30 (5 g / mL) and protein A-conjugated agarose bead (Repl iGen, Waltham, MA, USA). After washing, the protein bound to beads was eluted by boiling in NuPAGE LDS Sample Buffer (Thermo Fisher Scientific), and SDS-PAGE and immunoblotting (Reference Example 4 ). The eluted proteins separated by S-PAGE were separated by Coomassie
- alanine scanning mutagenesis assay was performed. (Amino acid residues 37 to 290 of R0SKR0S1) as a template and one of the amino acid residues from the 42nd (Gly) to the 54th (Ser) of R0S1 by PCR amplification was substituted with alanine A gene encoding the sequence was prepared.
- the PCR was performed using [Y. Lee, H., Kim, J. Chung, An antibody reactive to the Gly63-Lys68 epitope of NT-proBNP exhibits 0-glycosyl ation- independent binding, Exp. Mol. Med. 46 (2014) ell4].
- the primers and the PCR conditions used for the alanine substitution were as follows. After pre-denaturation of DNA at 95 ° C for 5 min, DNA denaturation at 95 ° C for 30 sec, binding of primer at 56 ° C for 30 sec, elongation at 72 ° C for 30 sec, and then 30 cycles of incubation at 72 ° C The incubation was terminated after 5 minutes of incubation.
- the gene coding for 3B20 scFv was amplified by PCR amplification by degenerate codon NNK, independently of A, C, G, or T; As a template.
- the first fragment was PCR amplified using forward primer (5'-CTGGCTGGTTTCGCTACCGTGGCC-3 '; SEQ ID NO: 19) and reverse primer (5'-TCTGGTGCAGTAGTAGGTGGC-3'; SEQ ID NO: 20);
- the second fragment was designated as forward primer (5'-GCCACCACTACTGCACCAGA [GGT / GGT / GGT / GGT / AAC / ATC / GAC / GCA] TGGGGCCAC-3 ';
- Protein bands of about 70 kDa and 260 kDa were cut out on an SDS-PAGE gel (Reference Example 5) to perform in-gel tryptic digestion [A. Shevchenko, H. Tomas, J. Havl is, J.V. Olsen, M. Mann, In-gel digestion for mass spectroscopic characterization of proteins and proteomes, Nat. Protoc. 1 (2006) 2856-2860). The cleaved protein bands were de-stained
- the extracted peptide sample was suspended in 0.1% formic acid in water, loaded onto an EASY-Spray C18 column (75 x 50 cm x 2) and eluted with 0.1% formic acid (in) at a flow rate of 300 nL / acetonitri le).
- MS spectra were recorded on a Q_ Exact ive hybrid quadrupole-Orbi trap mass spectrometer (Thermo Fisher Scientific) interfaced to a nano-ultra-HPLC system (Easy-nLCl000; Thermo Scientific).
- the obtained MS / MS raw files were converted into mzXML files using the Trans-Proteomic Pipeline (version 4.4) and analyzed using the Sequest (version 27) algorithm on a SORCERER (Sage-N Research, Milpitas, .
- the search was performed using the Intemational Protein Index human database (version 3.83, 186578 entries). Full trypsin-sensitive specificity and up to two missed cleavage sites were acceptable.
- the mass tolerances for precursor ions and fragment ions were set to lOppm and IDa, respectively. Fixed modification for conventional carbamidomethyl-cysteine and variable modi fi cation for methionine oxidation were used.
- Immunoprecipitation analysis was performed using a lysate of HEK293T cells transfected with a lentiviral vector encoding human ROS1 (full length) and 3B20 scFv-rFc fusion protein, with reference to Reference Example 5. Immunoprecipitated proteins were analyzed by immunoblotting using a commercially available anti-ROS1 antibody reactive to the C-terminal region of ROS1, and the results are shown in Figure Ib. . More specifically, Fig.
- 1b shows a lysate of HEK293T cells transfected with a lentiviral vector encoding human ROSl (full-length) with 3B20 scFv-rFc fusion protein 2019/107671 1 »(: 1/10/10 Public 018/002655
- Immunoprecipitation was performed by treating 3B20 scFv-rFc fusion protein with HEK293T cell lysate transfected with a lentiviral vector encoding human ROS1 (battlefield) or GFP (control) to examine the protein responsive to 3B20 scFv. Proteins bound to the 3B20 scFv protein were separated by SDS-PAGE. After electrophoresis, the gel was stained with Coomassie blue. Bands corresponding to 70 kDa and 260 kDa were collected from the gel and analyzed by liquid chromatography / MS. The obtained results are shown in FIG.
- the values listed in the transfected controle / transfected ROSl column represent the number of spectral counts derived from the LC-MS / MS data.
- the band of approximately 70 kDa is Hsp70, Hsp71 , GRP75 and GRP78. ≪ / RTI >
- an alanine scanning mutagenesis assay was performed using a recombinant ROS1 protein corresponding to amino acid residues 37-290 of the ROS1 protein.
- an R0S1 mutant in which the amino acid residue of any one of Gly42 to Ser54 of the recombinant ROS1 protein was substituted with alanine was prepared.
- the microtiter plate wells were coated with 3B20 scFv-CK fusion protein, BSA or irrelevant scFv-CK fusion protein and the plate incubated with alanine substituted ROSl-hFc fusion protein or wild type ROSl-hFc fusion protein Respectively.
- the amount of ROSl-hFc fusion protein bound to the plate was measured using HRP-conjugated anti-hFc antibody and ATBS solution. The results obtained are shown in Fig. 2A (coated with 3B20 scFv-CK fusion protein), 2b (coated with BSA), and 2c (coated with i rrelevant SCFV-CK fusion protein).
- the 3B20 scFv-CK fusion protein showed markedly decreased reactivity with the L45A mutation, the L47A mutation, and the G48A mutation of the R0S1 protein, while the other mutants showed similar reactivity with the wild-type R0S1 protein.
- the BSA or negative control scFv-Fc fusion protein did not react with the ROSl mutants. Based on these results, it was concluded that three residues of Leu45, Leu47 and Gly48 of ROS1 play an important role in binding properties to 3B20 scFv.
- three residues of Leu45, Leu47 and Gly48 of ROS1 play an important role in binding properties to 3B20 scFv.
- an H 3 R 3 site-directed mutagenesis library was constructed by the method described in Reference Example 7 to generate a monoclonal antibody clone that does not react with Hsp70 but reacts with ROS1.
- the H3R3 region (GGGGNIDA) of 3B20 scFv is composed of 8 amino acids,
- NNK phage display libraries were constructed using PCR primers designed to include N, N, K, N, G, and T respectively in each of the amino acid positions of H < 3 > Reference) .
- Forty-eight clones were randomly selected from each library and phage ELISA was performed on recombinant ROS1 and GRP75.
- a mAb clone that responds only to ROS1 in the first amino acid residue random library, but not GRP75.
- G glycine
- K lysine
- 3B20-G1K scFv-CK fusion protein was prepared. ELISA, immunoblotting and immunoprecipitation analysis of the prepared fusion proteins were performed in parallel with 3B20. More specifically, microtiter plate wells were incubated with 100 ng of recombinant ROSl
- a lysate of HEK293T cells transformed with the R0S1 (fulll eng) coding lentivirus vector (lane R) or the control vector (lane C; GFP) was applied to SDS-PAGE, transferred to nitrocellulose membranes and blocked , The membrane was incubated with 3B20, 3B20-G1K or control antibody (ab5512; Abeam) to perform immunoblotting.
- the obtained immunoblotting results are shown in Fig. 3C. As shown in FIG.
- Immunoprecipitation analysis was also performed as follows.
- the HEK293T cells transformed with the R0S1 (full-length) coding lentivirus vector (lane R) or the control vector (lane C; GFP) were lysed and the 3B20 (scFv) -rFc fusion protein and 3B20 (scFv) -GlK- Incubated with protein and reacted with protein A agarose beads. After washing, the proteins bound to the beads were eluted and subjected to SDS-PAGE. Proteins bound to beads were visualized by staining with Coomassie Blue. The obtained immunoprecipitation analysis result is shown in Fig.
- Example 9 IHC analysis of human lung cancer using B20-G1K monoclonal antibody
- human ROS1 full-length
- human non-neoplast ic lung tissue (benign bronchial epithelia), which were transformed with the coding lentiviral vector And alveolar pneumocytes (provided by Boramae Hospital, Seoul) were subjected to immunohistochemistry (IHC) and the results are shown in FIG.
- ROS1 is strongly expressed in both the cytoplasmic membrane and the cytoplasm as a result of IHC on HEK293T cells transformed with a lentiviral vector encoding human ROS1 (full-length) (X400) 4
- FIG. 4 shows the observation at x 400 in human lung cancer tissues, confirming the ROS1-positive result in the cytoplasmic membrane and the cytoplasm, and in particular, the ROS expression in the membrane was enhanced. As shown in FIG.
- HEK293T cells transformed with the R0S1 gene used as a positive control showed strong expression of ROS1 in membrane and cytoplasm (A); Interocular Non-neoplastic lung tissue is Benign bronchial epithelia and alveolar pneum ⁇ In R0S1- negative results have appeared (B); In human lung cancer tissues, ROS expression was observed in various degrees and in 10% of cases, ROS was localized in the cytoplasmic membrane, It was also confirmed to be expressed in the cytoplasm (CF).
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/767,245 US20230242670A1 (en) | 2017-11-29 | 2018-03-06 | Anti-ros1 antibody and use thereof |
KR1020187006693A KR102078775B1 (ko) | 2017-11-29 | 2018-03-06 | 항-ros1 항체 및 그의 용도 |
JP2020529420A JP7041265B2 (ja) | 2017-11-29 | 2018-03-06 | 抗-ros1抗体およびその用途 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762591974P | 2017-11-29 | 2017-11-29 | |
US62/591,974 | 2017-11-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2019107671A1 true WO2019107671A1 (ko) | 2019-06-06 |
Family
ID=66665052
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2018/002655 WO2019107671A1 (ko) | 2017-11-29 | 2018-03-06 | 항-ros1 항체 및 그의 용도 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20230242670A1 (ko) |
JP (1) | JP7041265B2 (ko) |
KR (1) | KR102078775B1 (ko) |
WO (1) | WO2019107671A1 (ko) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022155518A1 (en) | 2021-01-15 | 2022-07-21 | Seagen Inc. | Immunomodulatory antibody-drug conjugates |
WO2022170002A1 (en) | 2021-02-03 | 2022-08-11 | Seagen Inc. | Immunostimulatory compounds and conjugates |
WO2023215740A1 (en) | 2022-05-06 | 2023-11-09 | Seagen Inc. | Immunomodulatory antibody-drug conjugates |
WO2024030577A1 (en) | 2022-08-03 | 2024-02-08 | Seagen Inc. | Immunostimulatory anti-pd-l1-drug conjugates |
EP4321522A1 (en) | 2022-08-12 | 2024-02-14 | Seagen Inc. | Cytotoxic compounds and conjugates thereof |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120237530A1 (en) * | 2009-10-21 | 2012-09-20 | Hiroshima University | Integrin alpha 8-beta 1-specific monoclonal antibody |
US20130336923A1 (en) * | 2005-12-02 | 2013-12-19 | Dana-Farber Cancer Institute, Inc. | Carbonic Anhydrase IX (G250) Antibodies and Methods of Use Thereof |
WO2014016737A1 (en) * | 2012-07-24 | 2014-01-30 | Pfizer Inc. | Novel chicken monoclonal antibodies against human phosphorylated tau and uses thereof |
US20140243332A1 (en) * | 2013-02-27 | 2014-08-28 | Oregon Health & Science University | Methods of treating cancers characterized by aberrent ros1 activity |
US20150064187A1 (en) * | 2012-03-28 | 2015-03-05 | Hiroshima University | Fibrosis suppression by inhibiting integrin alpha-8 beta-1 function |
WO2017037220A1 (en) * | 2015-09-03 | 2017-03-09 | Ist Austria | Ros1 positive cancer treatment |
KR101736420B1 (ko) * | 2014-11-28 | 2017-05-16 | 에스지메디칼 주식회사 | 파툴린 특이적인 항체 및 이를 이용한 파툴린의 검출 방법 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110008347A1 (en) * | 2006-12-01 | 2011-01-13 | Agency For Science ,Technology And Research | Cancer-related protein kinases |
US9109259B2 (en) | 2010-06-22 | 2015-08-18 | Japanese Foundation For Cancer Research | Detection method for novel ROS1 fusions |
TWI585088B (zh) | 2012-06-04 | 2017-06-01 | 第一三共股份有限公司 | 作爲激酶抑制劑之咪唑并[1,2-b]嗒衍生物 |
-
2018
- 2018-03-06 US US16/767,245 patent/US20230242670A1/en active Pending
- 2018-03-06 KR KR1020187006693A patent/KR102078775B1/ko active IP Right Grant
- 2018-03-06 WO PCT/KR2018/002655 patent/WO2019107671A1/ko active Application Filing
- 2018-03-06 JP JP2020529420A patent/JP7041265B2/ja active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130336923A1 (en) * | 2005-12-02 | 2013-12-19 | Dana-Farber Cancer Institute, Inc. | Carbonic Anhydrase IX (G250) Antibodies and Methods of Use Thereof |
US20120237530A1 (en) * | 2009-10-21 | 2012-09-20 | Hiroshima University | Integrin alpha 8-beta 1-specific monoclonal antibody |
US20150064187A1 (en) * | 2012-03-28 | 2015-03-05 | Hiroshima University | Fibrosis suppression by inhibiting integrin alpha-8 beta-1 function |
WO2014016737A1 (en) * | 2012-07-24 | 2014-01-30 | Pfizer Inc. | Novel chicken monoclonal antibodies against human phosphorylated tau and uses thereof |
US20140243332A1 (en) * | 2013-02-27 | 2014-08-28 | Oregon Health & Science University | Methods of treating cancers characterized by aberrent ros1 activity |
KR101736420B1 (ko) * | 2014-11-28 | 2017-05-16 | 에스지메디칼 주식회사 | 파툴린 특이적인 항체 및 이를 이용한 파툴린의 검출 방법 |
WO2017037220A1 (en) * | 2015-09-03 | 2017-03-09 | Ist Austria | Ros1 positive cancer treatment |
Non-Patent Citations (1)
Title |
---|
LEE, HWA KYOUNG: "A point mutation in the heavy chain complementarity- determining region 3 (HCDR3) significantly enhances the specificity of an anti-ROSI antibody", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 493, 6 September 2017 (2017-09-06), pages 325 - 331, XP085230240, DOI: doi:10.1016/j.bbrc.2017.09.023 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022155518A1 (en) | 2021-01-15 | 2022-07-21 | Seagen Inc. | Immunomodulatory antibody-drug conjugates |
WO2022170002A1 (en) | 2021-02-03 | 2022-08-11 | Seagen Inc. | Immunostimulatory compounds and conjugates |
WO2023215740A1 (en) | 2022-05-06 | 2023-11-09 | Seagen Inc. | Immunomodulatory antibody-drug conjugates |
WO2024030577A1 (en) | 2022-08-03 | 2024-02-08 | Seagen Inc. | Immunostimulatory anti-pd-l1-drug conjugates |
EP4321522A1 (en) | 2022-08-12 | 2024-02-14 | Seagen Inc. | Cytotoxic compounds and conjugates thereof |
Also Published As
Publication number | Publication date |
---|---|
JP2021503931A (ja) | 2021-02-15 |
JP7041265B2 (ja) | 2022-03-23 |
US20230242670A1 (en) | 2023-08-03 |
KR102078775B1 (ko) | 2020-02-19 |
KR20190087954A (ko) | 2019-07-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102078775B1 (ko) | 항-ros1 항체 및 그의 용도 | |
CN110167967B (zh) | 针对抗pd-l1抗体的独特型抗体及其用途 | |
EP2183282A1 (en) | Antibodies specific for the c-terminal regulatory domain of egfr and their use | |
KR20110090985A (ko) | 인간 cxcl1 단백질의 면역학적 측정 방법 | |
JP6324970B2 (ja) | 抗ウロプラキンii抗体システムおよび方法 | |
US10809263B2 (en) | Antigenic composition for detecting auto-antibody with specific response to exosomal protein EIF3A, and method for diagnosing liver cancer using antigenic composition | |
KR20110040624A (ko) | 항-fasn 자가면역 항체를 포함하는 간암 진단 마커 및 이의 항원을 포함하는 간암 진단용 조성물 | |
JP2016510870A (ja) | 補体因子h関連タンパク質1検出のための剤、キットおよび方法 | |
WO2017155355A1 (ko) | Aimp2-dx2 단백질에 특이적으로 결합하는 항체 | |
CN116410322A (zh) | 抗人pcdh7蛋白的单克隆抗体及其应用 | |
WO2018135653A1 (ja) | 抗epha2抗体及びこれを用いたepha2の免疫学的検出 | |
AU2017219386B2 (en) | Antibody against EGFRvIII and use thereof | |
CN111303289B (zh) | 抗人Tn型糖基化MUC1抗体及其用途 | |
KR20220055423A (ko) | SARS-CoV-2 특이적 신규 항체를 이용한 SARS-CoV-2의 검출방법 | |
KR102119783B1 (ko) | 인간 상피 성장 인자 수용체 변이체 ⅲ에 결합하는 항체 및 그의 항체 단편 | |
CN108727493B (zh) | 抗Stathmin单克隆抗体及其用途 | |
Lee et al. | A point mutation in the heavy chain complementarity-determining region 3 (HCDR3) significantly enhances the specificity of an anti-ROS1 antibody | |
KR102172541B1 (ko) | Bag2 항체를 이용한 암 진단용 조성물 및 이를 이용한 방법 | |
ES2694296T3 (es) | Anticuerpos monoclonales anti-pVHL y usos de los mismos | |
KR102590757B1 (ko) | GKN1(Gastrokine 1) 특이적 항체 및 이의 용도 | |
CN112724253B (zh) | 抗人穹窿体蛋白的抗体及其应用 | |
US20230194534A1 (en) | Methods for diagnosing cancer using anti-bag2 antibody | |
KR20210067120A (ko) | Cobll1 단백질 특이 항체 또는 이의 항원 결합 단편, 및 이의 용도 | |
WO2012077643A1 (ja) | cofilin1タンパク質の免疫学的測定方法 | |
이화경 | Production of an anti-ROS1 scFv antibody with enhanced specificity by a point mutation in the HCDR3 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref document number: 20187006693 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020187006693 Country of ref document: KR |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18884216 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2020529420 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 18884216 Country of ref document: EP Kind code of ref document: A1 |